PDK1 disruptors and modulators: a patent review

Bibliography

• Bunnage ME. Getting pharmaceutical R&D back on target. Nat Chem Biol 2011;7:335-9
   PubMed Web of Science ®Google Scholar
• Gashaw I, Ellinghaus P, Sommer A, Asadullah K. What makes a good drug target? Drug Discov Today 2011;6:1037-43
   Google Scholar
• Hoelder S, Clarke PA, Workman P. Discovery of small molecule drugs: successes, challenges and opportunities. Mol Oncol 2012;6:155-76
   PubMed Web of Science ®Google Scholar
• Carnero A, Blanco-Aparicio C, Renner O, et al. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 2008;8:187-98
   PubMed Web of Science ®Google Scholar
• Chiang GG, Abraham RT. Targeting the mTOR signaling network in cancer. Trends Mol Med 2007;13:433-42
   PubMed Web of Science ®Google Scholar
• Cicenas J. The potential role of Akt phosphorylation in human cancers. Int J Biol Markers 2008;23:1-9
   PubMed Web of Science ®Google Scholar
• Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008;27:5497-510
   PubMed Web of Science ®Google Scholar
• Brachmann S, Fritsch C, Maira SM, Garcia-Echeverria C. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents. Curr Opin Cell Biol 2009;21:194-8
   PubMed Web of Science ®Google Scholar
• Fasolo A, Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2008;17:1717-34
   PubMed Web of Science ®Google Scholar
• Garcia-Echeverria C, Sellers WR. Drug discovery approaches targeting the PI3K/Akt pathway in cancer. Oncogene 2008;27:5511-26
   PubMed Web of Science ®Google Scholar
• Lindsley CW, Barnett SF, Layton ME, Bilodeau MT. The PI3K/Akt pathway: recent progress in the development of ATP-competitive and allosteric Akt kinase inhibitors. Curr Cancer Drug Targets 2008;8:7-18
   PubMed Web of Science ®Google Scholar
• Maira SM, Stauffer F, Brueggen J, et al. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 2008;7:1851-63
   PubMed Web of Science ®Google Scholar
• Raimondi C, Falasca M. Targeting PDK1 in cancer. Curr Med Chem 2011;18:2763-9
   PubMed Web of Science ®Google Scholar
• Biondi RM, Komander D, Thomas CC, et al. High resolution crystal structure of the human PDK1 catalytic domain defines the regulatory phosphopeptide docking site. EMBO J 2002;21:4219-28
   PubMed Web of Science ®Google Scholar
• Casamayor A, Morrice NA, Alessi DR. Phosphorylation of Ser-241 is essential for the activity of 3 - phosphoinositide-dependent protein kinas -1: identification of five sites of phosphoylation in vivo. Biochem J 1999;342:287-92
   PubMed Web of Science ®Google Scholar
• Park J, Hill MM, Hess D, et al. Identification of tyrosine phosphorylation sites on 3-phosphoinositide-dependent protein kinase-1 and their role in regulating kinase activity. J Biol Chem 2011;276:37459-71
   Google Scholar
• Wick MJ, Ramos FJ, Chen H, et al. Mouse 3-phosphoinositide-dependent protein kinase-1 undergoes dimerization and trans-phosphorylation in the activation loop. J Biol Chem 2003;278:42913-19
   PubMedGoogle Scholar
• Scheid MP, Parsons M, Woodgett JR. Phosphoinositide-dependent phosphorylation of PDK1 regulates nuclear translocation. Mol Cell Biol 2005;25:2347-63
   PubMedGoogle Scholar
• Barile E, De SK, Pellecchia M. PDK1 inhibitors. Pharm Pat Anal 2012;1:145-63
   PubMedGoogle Scholar
• Raimondi C, Falasca M. Targeting PDK1 in cancer. Curr Med Chem 2011;18:2763-9
   PubMed Web of Science ®Google Scholar
• Peifer C, Alessi DR. Small-molecule inhibitors of PDK1. Chem Med Chem 2008;3:1810-38
   Web of Science ®Google Scholar
• Bayascas JR. PDK1. The major transducer of PI3-kinase actions. Curr Top Microbiol Immunol 2010;346:9-29
   PubMed Web of Science ®Google Scholar
• Mora A, Komander D, van Aalten DM, Alessi DR. PDK1, the master regulator of AGC kinase signal transduction. Semin Cell Dev Biol 2004;15:161-70
   PubMed Web of Science ®Google Scholar
• Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 2010;11:9-22
   PubMed Web of Science ®Google Scholar
• Alessi DR, James SR, Downes CP, et al. Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 1997;7:261-9
   PubMed Web of Science ®Google Scholar
• Filippa N, Sable CL, Hemmings BA, Van Obberghen E. Effect of phosphoinositide-dependent kinase 1 on protein kinase B translocation and its subsequent activation. Mol Cell Biol 2000;20:5712-21
   PubMed Web of Science ®Google Scholar
• Milburn CC, Deak M, Kelly SM, et al. Binding of phosphatidylinositol 3,4,5-trisphosphate to the pleckstrin homology domain of protein kinase B induces a conformational change. Biochem J 2003;375:531-8
   PubMed Web of Science ®Google Scholar
• Biondi RM, Kieloch A, Currie RA, et al. The PIF-binding pocket in PDK1 is essential for activation of S6K and SGK, but not PKB. EMBO J 2001;20:4380-90
   PubMed Web of Science ®Google Scholar
• Casamayor A, Torrance PD, Kobayashi T, et al. Functional counterparts of mammalian protein kinases PDK1 and SGK in budding yeast. Curr Biol 1999;9:186-97
   PubMed Web of Science ®Google Scholar
• Engelman JA, Chen L, Tan X, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351-6
   PubMed Web of Science ®Google Scholar
• Bayascas JR, Leslie NR, Parsons R, et al. Hypomorphic mutation of PDK1 suppresses tumorigenesis in PTEN (+/-) mice. Curr Biol 2005;15:1839-46
   PubMed Web of Science ®Google Scholar
• Pearce LR, Komander D, Alessi DR. The nuts and bolts of AGC protein kinases. Nat Rev Mol Cell Biol 2010;1:9-22
   Google Scholar
• WIPS Global. Available from: www.wispglobal.com
   Google Scholar
• Cas databases. Available from: www.cas.org
   Google Scholar
• European Patent Office. Available from: www.epo.org
   Google Scholar
• Eli Lilly and Co. Bisindolylmaleimides convenant pour le traitement du cancer de la prostage et de maladies induites par Akt. WO041953; 2005
   Google Scholar
• AstraZeneca UK Ltd. Substituted heterocycles and their use as chk1, PDK1 and pak inhibitors. WO106326; 2006
   Google Scholar
• Schering AG. 5-ureido-3-[(4-(3-methoxyphenyl) pyrrol-2-yl)methylene]indolin-2-one and derivatives; inhibition of phosphoinositide-dependent kinase-1 (PDK-1). US07105563; 2006
   Google Scholar
• Sunesis Pharmaceuticals. Pyridinonyl PDK1 inhibitors. WO005457; 2008
   Google Scholar
• Novartis AG. Biologically active preparation (variants) and a method for the production thereof (variants). WO054238; 2008
   Google Scholar
• SGX Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators. WO015124; 2006
   Google Scholar
• Vernalis Cambridge Ltd. Isoxazole compounds as inhibitors of heat shock proteins. WO087707; 2004
   Google Scholar
• Vertex Pharmaceuticals, Inc. Indazole compounds useful as protein kinase inhibitors. WO064397; 2003
   Google Scholar
• Wyeth. 10,11-dimethoxydibenzo[c,f]-2,7-naphthyridin-6-amine; inhibiting pyruvate dehydrogenase kinase PDK-1in a cell; antiproliferative agent; brain, colon cancer, leukemia, prostate and breast cancer. US0135429; 2007
   Google Scholar
• Phosphosites GmbH. Use of a compound of formula I for making a pharmaceutical composition. EP1486488; 2004
   Google Scholar
• Merck & Co., Inc. Pyrrolo [2, 3-d] pyrazin-7-yl pyrimidine compounds. WO076327; 2011
   Google Scholar
• Merck & Co., Inc. Aminopyridine derivatives for treating tumors and inflammatory diseases. WO006567; 2011
   Google Scholar
• Merck & Co., Inc. Therapeutic compounds. WO017047; 2010
   Google Scholar
• Merck & Co., Inc. Inhibitors of phosphoinositide dependent kinase 1 (PDK1). WO065384; 2010
   Google Scholar
• Erlanson DA, Arndt JW, Cancilla MT, et al. Discovery of a potent and highly selective PDK1 inhibitor via fragment-based drug discovery. Bioorg Med Chem Lett 2011;21:3078-83
   PubMed Web of Science ®Google Scholar
• Nagashima K, Shumway SD, Sathyanarayanan S, et al. Genetic and pharmacological inhibition of PDK1 in cancer cells: characterization of a selective allosteric kinase inhibitor. J Biol Chem 2011;286:6433-48
   PubMed Web of Science ®Google Scholar
• Merck & Co., Inc. Dérivés de 3-([1, 2, 3] triazol-4-yl)-pyrrolo[2,3-b]pyridine. WO065384A1; 2010
   Google Scholar
• Merck & Co., Inc. 3-([1, 2, 3] triazole-4-yl)-pyrrolo[2,3-b]pyridine derivates. WO 127754; 2010
   Google Scholar
• Boehringer Ingelheim. Purine derivatives and their use in the treatment of proliferative diseases. WO107444; 2008
   Google Scholar
• Boehringer Ingelheim. Heterocyclyl carbonic acid amides as antiproliferative agents, pdkl inhibitors. WO007114; 2010
   Google Scholar
• Boehringer Ingelheim. Pyridons as PDK1 inhibitors. WO007116; 2010
   Google Scholar
• GlaxoSmithK line. Chemical compounds. WO019637; 2010
   Google Scholar
• GlaxoSmithKline. Chemical compounds. WO120854; 2010
   Google Scholar
• Novartis. 2-arylaminoquinazolines for treating proliferative diseases. WO153313; 2009
   Google Scholar
• Novartis. 2-arylaminoquinazolines for treating proliferative diseases. WO079988; 2008
   Google Scholar
• Sunesis & Biogen. Heterocyclic compounds useful as PDK1 inhibitors. WO044157; 2011
   Google Scholar
• Wyeth. Pyrimido [5,4-c] quinoline-2, 4-diamine derivatives and methods of use thereof. WO109599; 2008
   Google Scholar
• Wyeth. Benzo[c][2,7]naphthyridine derivatives, and their use as kinase inhibitors. WO109613; 2008
   Google Scholar
• Nittoli T, Dushin RG, Ingalls C, et al. The identification of 8, 9-dimethoxy-5-(2-aminoalkoxy-pyridin-3-yl)-benzo[c] [2,7] naphthyridin-4-yl amines as potent inhibitors of 3-phosphoinositide-dependentkinase-1 (PDK-1). Eur J Med Chem 2010;45:1379-86
   PubMedGoogle Scholar
• The Ohio State University Research Foundation. Anti-infective agents against intracellular pathogens. US0111799; 2009
   Google Scholar
• Joseph A, Timothy C, Kevin G, et al. Heterocyclic compounds useful as PDK1 inhibitors. US0208819; 2012
   Google Scholar
• Biondi RM, Laura AL, Lopez G, et al. Chimeric PDK1 kinases. US0017701; 2014
   Google Scholar
• Boehringer Ingelheim International Gmbh. Pyridons as PDK1 inhibitors. US0269958; 2011
   Google Scholar
• Merck Patent Gmbh. 3-hetaryl-substituted pyrrolo [2,3b] pyridine derivatives as PDK1 inhibitors. US0245355; 2013
   Google Scholar
• Merck Patent Gmbh. 3-hetaryl-substituted pyrrolo [2, 3 b] pyridine derivatives as PDK1 inhibitors. WO072200; 2012
   Google Scholar
• Schering Corp. Novel thiazole-carboximide derivatives as PDK1 inhibitors. WO036974; 2012
   Google Scholar
• Schering Corp. Novel thiazole-carboxamide derivatives as PDK1 inhibitors. WO058174A1; 2012
   Google Scholar
• Hon-Chung T, Sunil P, Oliver FT. Novel thiazol-carboximide derivatives as PDK1 inhibitors. US0165450; 2013
   Google Scholar
• Schering Corp. Novel heteroaryl-carboxamide derivatives as PDK1 inhibitors. WO058176; 2012
   Google Scholar
• Schering Corp. Inhibitors of phosphoinositide dependent kinase 1 (PDK1). WO137219; 2011
   Google Scholar
• Sunil P, Pau RM, Ang L, et al. Inhibitors of phosphoinositide dependent kinase 1 (PDK1). US0053382; 2013
   Google Scholar
• Brears DJ, Hariprasad V, Venkataswamy S, et al. Substituted 3-(1h-benzo[d]imidazol-2-yl)-1h-indazole analogs as inhibitors of the PDK1 kinase. US0277229; 2012
   Google Scholar
• University of Utah Research Foundation. Substituted 3-(1h-benzo[d]imidazol-2-yl)-1h-indazole analogs as inhibitors of the PDK1 kinase. WO135799; 2012
   Google Scholar
• Universities Des Saarlandes. High resolution complex structure and allosteric effects of low molecular weight activators on the protein kinase PDK1. US0003668; 2012
   Google Scholar
• Xie Z, Yuan H, Yin Y, et al. 3-phosphoinositide-dependent protein kinase-1 (PDK1) promotes invasion and activation of matrix metalloproteinases. BMC Cancer 2006;6:77
   PubMed Web of Science ®Google Scholar
• Yang KJ, Shin S, Piao L, et al. Regulation of 3-phosphoinositide-dependent protein kinase-1 (PDK1) by Src involves tyrosine phosphorylation of PDK1 and Src homology 2 domain binding. J Biol Chem 2008;283;1480-91
   PubMedGoogle Scholar
• Tan J, Yu Q. Molecular mechanisms of tumor resistance to PI3K-mTOR-targeted therapy. Chin J Cancer 2013;32:376-9
   PubMedGoogle Scholar
• Tan J, Li Z, Lee PL, et al. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. Cancer Discov 2013;3:1156-71
   PubMed Web of Science ®Google Scholar